about
Development and validation of a clinical scale for rating the severity of blepharospasm.Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7Chiari type 1 malformation in Neurofibromatosis type 1: experience of a center and review of the literature.Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm.Donepezil in the treatment of progressive supranuclear palsy.Novel parkin mutations detected in patients with early-onset Parkinson's disease.Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.Cognitive concomitants of dopamine system stimulation in parkinsonian patients.Abnormal Temporal Coupling of Tactile Perception and Motor Action in Parkinson's Disease.Tourette disorder spectrum maps to chromosome 14q31.1 in an Italian kindred.Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease.Tardive dyskinesias in the elderly.A comparative study of primary and secondary hemifacial spasm.Kinematic and diffusion tensor imaging definition of familial Marcus Gunn jaw-winking synkinesis.Levodopa-induced dyskinesias.Role of pramipexole in the management of Parkinson's disease.ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease.Pathophysiology of tics and Tourette syndrome.Diffusion tensor imaging in primary cervical dystonia.Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Head trauma in primary cranial dystonias: a multicentre case-control study.Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control studyDrug Insight: new drugs in development for Parkinson's disease.Is increased blinking a form of blepharospasm?Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment.Altered Kinematics of Facial Emotion Expression and Emotion Recognition Deficits Are Unrelated in Parkinson's Disease.Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.Craniocervical dystonia: clinical and pathophysiological features.Soluble and controlled-release preparations of levodopa: do we really need them?Pathophysiology of pain and fatigue in Parkinson's disease.Motor response complications with chronic levodopa therapy.Selegiline: a reappraisal of its role in Parkinson disease.Fatigue in Parkinson's disease: motor or non-motor symptom?Facial bradykinesia.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Parkinsonian patients and poor awareness of dyskinesias.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Is tremor in dystonia a phenotypic feature of dystonia?
P50
Q27333214-7E6CC7C3-CE74-4BFA-8FE4-5C9AFFCEDF8EQ28205082-4EF24985-AF2C-4D2C-855B-B5BF4BC0B64AQ31058912-DB1768FD-A757-4409-8AAB-31496448A061Q31143768-5DFEE7EF-345C-482E-BE17-7414248E20E4Q32066353-7888910B-B70A-4F2E-97F2-BB3929FE9062Q33209648-1D22A95A-317B-4B25-9F87-33A54D3616AAQ33627221-F018B536-771D-413B-A3AB-4DBE028A4A20Q33628911-5A62050F-4781-4CF7-BA57-2306BFFE69C3Q33629294-63471BCF-2786-4924-A11F-0E257A932FE7Q33766092-43788DFE-5872-4BAE-AC68-8EE65BE0AFA0Q34207624-51AFD047-CE8C-492F-BAA3-BF95D298C15DQ34274448-DF25D122-B1D4-4AB8-84D1-4291B3A2186DQ34351580-93D7B591-292C-47D1-B3B6-6ACB83DCE635Q34465779-67623D9C-7501-4282-AC1A-00F2AC3857A5Q34501739-26C58450-87FF-46F8-819E-C8C642AA207DQ34532256-C5C67D8B-2872-48FC-B751-98D7047EE41DQ34618170-218EAE3B-0250-4F59-A757-07F8C681254CQ34623437-929E86E9-C663-4219-9132-A8B0B2F7E95AQ34626200-C262C5B0-BFD3-40DF-926B-766BB4B10BE7Q35186212-513C4969-AC17-407B-ABA7-CF7D65267116Q35484584-986C0A2F-6099-444B-BAEC-6BEB4F18A061Q35969183-EA4DC5A7-465F-498F-8B3D-C2B3831C95E8Q36226868-F18F8E8B-621D-4F40-93E3-E2F77D89E056Q36227210-8FFE109E-9882-433E-93CB-F06A88E0CF10Q36631654-F25A8BDC-AAAF-4B2E-8795-C810F3DB53B9Q37039678-8961677A-B397-4FF6-8332-89FF24C5D9E7Q37385804-6EB2B56E-7DB8-41CC-A28B-C8A9E72C66DDQ37500580-88E692C5-92EB-47C7-9ACE-35191EC24601Q37716740-CF0E6FF3-A7DE-4D79-9854-88148A562827Q37768836-261CA410-4CE3-4C6D-9CFA-6D4FADE926C1Q37809798-70D52B6C-F60E-43BB-AF0E-39E71ED59E91Q37968061-ABD5D7B6-52E9-42EE-A1B2-AFBF452958C0Q37991081-900583B3-C1C8-412C-B84E-E4F2FF37A0BEQ38010624-82B6862D-7524-422E-8415-7174B87ECB06Q38056273-D26A29CA-F779-43F4-A640-41F39FA401BDQ38067071-0128EE03-2123-41EF-8FA1-1802208ABC4AQ38070888-9F9DC90A-7283-48C1-AFFC-B8399698A0B3Q38201010-65BC25D6-F83F-4CCA-8D17-8B163DCE85A8Q38219351-9F015776-6D9C-472E-9921-57925B5563F0Q38348504-89907D83-79C4-4CAA-A423-C870AC96E4F3
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovanni Fabbrini
@ast
Giovanni Fabbrini
@en
Giovanni Fabbrini
@es
Giovanni Fabbrini
@nl
Giovanni Fabbrini
@sl
type
label
Giovanni Fabbrini
@ast
Giovanni Fabbrini
@en
Giovanni Fabbrini
@es
Giovanni Fabbrini
@nl
Giovanni Fabbrini
@sl
prefLabel
Giovanni Fabbrini
@ast
Giovanni Fabbrini
@en
Giovanni Fabbrini
@es
Giovanni Fabbrini
@nl
Giovanni Fabbrini
@sl
P106
P21
P31
P4012
P496
0000-0001-7614-8771
P569
2000-01-01T00:00:00Z